Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
J Virol. 2024 Jul 23;98(7):e0079424. doi: 10.1128/jvi.00794-24. Epub 2024 Jun 28.
Coronavirus disease 2019 (COVID-19) has claimed millions of lives since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and lung disease appears the primary cause of death in COVID-19 patients. However, the underlying mechanisms of COVID-19 pathogenesis remain elusive, and there is no existing model where human disease can be faithfully recapitulated and conditions for the infection process can be experimentally controlled. Herein we report the establishment of an human precision-cut lung slice (hPCLS) platform for studying SARS-CoV-2 pathogenicity and innate immune responses, and for evaluating the efficacy of antiviral drugs against SARS-CoV-2. We show that while SARS-CoV-2 continued to replicate during the course of infection of hPCLS, infectious virus production peaked within 2 days, and rapidly declined thereafter. Although most proinflammatory cytokines examined were induced by SARS-CoV-2 infection, the degree of induction and types of cytokines varied significantly among hPCLS from individual donors. Two cytokines in particular, IP-10 and IL-8, were highly and consistently induced, suggesting a role in the pathogenesis of COVID-19. Histopathological examination revealed focal cytopathic effects late in the infection. Transcriptomic and proteomic analyses identified molecular signatures and cellular pathways that are largely consistent with the progression of COVID-19 in patients. Furthermore, we show that homoharringtonine, a natural plant alkaloid derived from , not only inhibited virus replication but also production of pro-inflammatory cytokines, and thus ameliorated the histopathological changes caused by SARS-CoV-2 infection, demonstrating the usefulness of the hPCLS platform for evaluating antiviral drugs.
Here, established an human precision-cut lung slice platform for assessing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, viral replication kinetics, innate immune response, disease progression, and antiviral drugs. Using this platform, we identified early induction of specific cytokines, especially IP-10 and IL-8, as potential predictors for severe coronavirus disease 2019 (COVID-19), and uncovered a hitherto unrecognized phenomenon that while infectious virus disappears at late times of infection, viral RNA persists and lung histopathology commences. This finding may have important clinical implications for both acute and post-acute sequelae of COVID-19. This platform recapitulates some of the characteristics of lung disease observed in severe COVID-19 patients and is therefore a useful platform for understanding mechanisms of SARS-CoV-2 pathogenesis and for evaluating the efficacy of antiviral drugs.
建立人类 肺切片平台,用于评估严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染、病毒复制动力学、固有免疫反应、疾病进展和抗病毒药物。
利用该平台,我们发现了特定细胞因子(尤其是 IP-10 和 IL-8)的早期诱导,它们可能是严重 2019 冠状病毒病(COVID-19)的潜在预测因子,并揭示了一个迄今为止尚未被认识的现象,即在感染后期,传染性病毒消失,但病毒 RNA 持续存在,肺部组织病理学开始出现。这一发现可能对 COVID-19 的急性和急性后后遗症都具有重要的临床意义。
该平台再现了一些在严重 COVID-19 患者中观察到的肺部疾病特征,因此是研究 SARS-CoV-2 发病机制和评估抗病毒药物疗效的有用平台。
我们建立了一种人类 精密肺切片平台,用于研究 SARS-CoV-2 的发病机制和先天免疫反应,以及评估抗病毒药物对 SARS-CoV-2 的疗效。